Personalised human albumin in patients with cirrhosis and ascites: design and rationale for the ALB-TRIAL - a randomised clinical biomarker validation trial
Introduction Human albumin is used in the treatment of complications of cirrhosis. However, the use of long-term human albumin administration is costly and resource demanding for both patients and healthcare systems. A precision medicine approach with biomarkers to predict human albumin treatment re...
Similar Items
-
Plasma angiopoietin 2 as a novel prognostic biomarker in alcohol-related cirrhosis and hepatitis
by: Victoria Tatiana Kronsten, et al.
Published: (2022-03-01) -
Novel Morphological Profiling Assay Connects ex Vivo Endothelial Cell Responses to Disease Severity in Liver Cirrhosis
by: Rudmer J. Postma, et al.
Published: (2024-01-01) -
Cross-alteration of murine skin and tick microbiome concomitant with pathogen transmission after Ixodes ricinus bite
by: Nathalie Boulanger, et al.
Published: (2023-11-01) -
Copeptin in acute decompensation of liver cirrhosis: relationship with acute-on-chronic liver failure and short-term survival
by: Annarein J. C. Kerbert, et al.
Published: (2017-12-01) -
Oncofetal Protein CRIPTO Is Involved in Wound Healing and Fibrogenesis in the Regenerating Liver and Is Associated with the Initial Stages of Cardiac Fibrosis
by: Sofia Karkampouna, et al.
Published: (2021-11-01)